Development of a Multi-omics Prediction Model for Immunotherapy Response in Triple-Negative Breast Cancer Subtypes

This is a retrospective study involving the collection and analysis of existing clinical data from breast cancer patients who received immunotherapy or neoadjuvant immunotherapy between January 1, 2015, and September 30, 2023. No new interventions are administered as part of this study. The data includes diagnostic puncture tissue, residual tumor tissue post-surgery, blood samples, and imaging data. These samples are analyzed using multi-omics approaches (proteomics, transcriptomics, metabolomics) and advanced imaging techniques (imaging mass cytometry and spatial transcriptomics) to build a predictive model for immunotherapy efficacy.